Pharma Mar SA (ES:PHM) has released an update.
PharmaMar Group reports a slight 1% increase in total revenues to 80.8 million euros for the first half of 2024, buoyed by royalty income growth of 16% and a significant 85% jump in raw material sales. Despite a dip in oncology sales, the company’s net profit stands at 3.5 million euros, with research and development investments up 10%. The financial health of the company is further indicated by a 9% reduction in debt and a strong cash position.
For further insights into ES:PHM stock, check out TipRanks’ Stock Analysis page.